English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Neuroblastoma (NB) is one of the most common types of extracranial malignant solid tumor in infants and children. MicroRNA-143 (miR-143) was reported to be dysregulated in several human cancers. However, the function and mechanism of miR-143 in NB are still unclear. The purpose of this study was to explore the biological functions of miR-143 in NB progression. Material and methods: The expression of miR-143 in 32 NB tissue samples and 4 NB cell lines was detected by quantitative real-time PCR. Then, bioinformatics analysis combined with luciferase reporter assay were used to identify the target gene of miR-143 in SK-N-SH cells. Cell proliferation, migration and invasion assay were performed to investigate the roles of miR-143 in NB progression. Results: Our study revealed that miR-143 was significantly downregulated in NB tissues as well as cell lines. Bone morphogenetic protein-7 (BMP7) was a direct target of miR-143 in NB cells and inversely associated with the expression of miR-143 in NB tissues. Overexpression of miR-143 inhibited NB cell proliferation, migration and invasion through targeting BMP7. Conclusions: Our data for the first time demonstrated that miR-143 functions as a tumor suppressor in NB by directly targeting BMP7, and also suggest miR-143 as a potential thera peutic target for NB patients in the future.

MicroRNA-143 functions as a tumor suppressor in neuroblastoma by targeting bone morphogenetic protein-7